Search Results - "Kalinin, R S"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    KDM5 Family Demethylase Inhibitor KDOAM-25 Reduces Entry of SARS-CoV-2 Pseudotyped Viral Particles into Cells by Knyazev, E. N., Kalinin, R. S., Abrikosova, V. A., Mokrushina, Yu.A., Tonevitskaya, S. A.

    “…We studied the effect of KDM5 family demethylase inhibitors (JIB-04, PBIT, and KDOAM-25) on the penetration of SARS-CoV-2 pseudotyped viruses into…”
    Get full text
    Journal Article
  2. 2

    Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival by Kalinin, R. S., Ukrainskaya, V. M., Chumakov, S. P., Moysenovich, A. M., Tereshchuk, V. M., Volkov, D. V., Pershin, D. S., Maksimov, E. G., Zhang, H., Maschan, M. A., Rubtsov, Y. P., Stepanov, A. V.

    Published in Frontiers in molecular biosciences (13-10-2021)
    “…CAR-T cell therapy is the most advanced way to treat therapy resistant hematologic cancers, in particular B cell lymphomas and leukemias, with high efficiency…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6

    Molecular Approaches to Safe and Controlled Engineered T-cell Therapy by Kalinin, R S, Petukhov, A V, Knorre, V D, Maschan, M A, Stepanov, A V, Gabibov, A G

    Published in Actanaturae (01-04-2018)
    “…Chimeric antigen receptor-modified T-cell therapy (CAR-T therapy) is one of the fastest developing areas of immuno-oncology. Over the past decade, it has…”
    Get full text
    Journal Article
  7. 7

    Directed Change in TNFα Specificity to Create DR5 Antagonists by Ukrainskaya, V. M., Bobik, T. V., Argentova-Stevens, A., Slutskaya, E. A., Kalinin, R. S., Gabibov, A. G., Stepanov, A. V.

    “…Death receptor 5 (DR5) is a promising target for antitumor therapy due to its high expression on different tumor cells. Resistance of various tumor cells…”
    Get full text
    Journal Article
  8. 8

    Human IL-36RA production in Escherichia coli with coexpression of E. coli methionine aminopeptidase. II. Comparison of IL-36RA biological activity from different strains by Kolobov, A. A., Kondratyeva, E. V., Sharafutdinova, T. A., Kalinin, R. S., Nimiritsky, P. P., Stefanov, V. E., Petrov, A. V.

    Published in Cell and tissue biology (01-11-2017)
    “…Proinflammatory cytokines of the interleukin-36 (IL-36) family are involved in the pathogenesis of different skin diseases in human and mice. Administration of…”
    Get full text
    Journal Article
  9. 9

    Human IL-36RA production in Escherichia coli with coexpression of E. coli methionine aminopeptidase. I. Comparison of IL-36RA production in different strains by Kolobov, A. A., Kondratyeva, E. V., Kudling, T. V., Karasev, M. M., Kalinin, R. S., Khizhina, A. A., Nimiritsky, P. P., Stefanov, V. E., Petrov, A. V.

    Published in Cell and tissue biology (01-11-2017)
    “…Generalized pustular psoriasis (GPP) is a rare, sometimes lethal, form of psoriasis caused by series of mutations in the interleukin-36 receptor antagonist…”
    Get full text
    Journal Article
  10. 10

    Diagnostic markers of betaherpesvirus 6 infection of A and B types in children with respiratory diseases by O. V. Goleva, I. V. Babachenko, E. V. Sharipova, Е. А. Murina, Yu. A. Eismont, R. S. Kalinin, A. B. Chukhlovin, Z. А. Osipova, A. L. Mukomolova, A. V. Krylov, O. S. Glotov

    Published in Zhurnal infektologii (01-04-2022)
    “…Objective: to reveal the prevalence of infection by various variants of betaherpesvirus 6 А/В types in children with clinical manifestations of acute…”
    Get full text
    Journal Article
  11. 11